CD274 and neoplasm: The classification of tumor immune signatures has been proven to be effective in predicting the responsiveness of anti-PD-L1 therapy across a range of cancers, especially in non-small cell lung cancer (NSCLC) (1) and metastatic urothelial cancer (mUC) (17), with immune desert tumors being the poorest responders (18).